MN HF4278

Health plan companies cannot restrict where enrollees receive services for diagnosis and treatment of rare diseases or conditions.

Rare disease or condition is defined as any disease affecting fewer than 200,000 persons in the United States, or affecting more than 200,000 persons with a drug treatment designated under federal law (21 U.S.C. § 360bb).

Cost-sharing requirements and benefit limitations for rare disease treatment must not be greater or more restrictive than requirements for in-network medical treatment.

This requirement does not apply to coverage provided through public health care programs under Minnesota Statutes chapters 256B or 256L.

The law is effective July 1, 2020, and applies to health plans offered, issued, or renewed on or after that date.